Business Description
Mendus AB
ISIN : SE0022239950
Compare
Compare
Traded in other countries / regions
IMMU.Sweden1YG0.GermanyIMMUs.UK IPO Date
2019-08-09Description
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.68 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 41.9 | |||||
| 3-Year EPS without NRI Growth Rate | 41.1 | |||||
| 3-Year FCF Growth Rate | 19.8 | |||||
| 3-Year Book Growth Rate | -39.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 48.49 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.19 | |||||
| Quick Ratio | 8.19 | |||||
| Cash Ratio | 6.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -68.5 | |||||
| Shareholder Yield % | -65.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -21.35 | |||||
| ROA % | -19.53 | |||||
| ROIC % | -22.57 | |||||
| 3-Year ROIIC % | -26.28 | |||||
| ROC (Joel Greenblatt) % | -320.93 | |||||
| ROCE % | -20.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.75 | |||||
| Price-to-Tangible-Book | 3.14 | |||||
| EV-to-EBIT | -3 | |||||
| EV-to-EBITDA | -3.16 | |||||
| EV-to-FCF | -2.7 | |||||
| Price-to-Net-Current-Asset-Value | 3.91 | |||||
| Price-to-Net-Cash | 5.95 | |||||
| Earnings Yield (Greenblatt) % | -33.26 | |||||
| FCF Yield % | -29.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mendus AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -3.514 | ||
| Beta | 0 | ||
| Volatility % | 33.36 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0 | ||
| 20-Day SMA (kr) | 32.7 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 32.7 - 32.7 | ||
| Shares Outstanding (Mil) | 50.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mendus AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mendus AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mendus AB Frequently Asked Questions
What is Mendus AB(CHIX:IMMUs)'s stock price today?
The current price of CHIX:IMMUs is kr32.70. The 52 week high of CHIX:IMMUs is kr32.70 and 52 week low is kr32.70.
When is next earnings date of Mendus AB(CHIX:IMMUs)?
The next earnings date of Mendus AB(CHIX:IMMUs) is 2024-11-08.
Does Mendus AB(CHIX:IMMUs) pay dividends? If so, how much?
Mendus AB(CHIX:IMMUs) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers